PLAU and breast cancer: The second LOE-1 study to have validated the prognostic utility of uPA and PAI-1 in breast cancer involved a pooled analysis of individual patient demographics data from 18 European datasets (n = 8,377) and was performed by the European Organization for Research and Treatment of Cancer (EORTC) Receptor and Biomarker group [9].